These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22777832)

  • 21. Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
    Kaderi ASA; Sabita J; Tiwari VK; Pawar A; Niyogi D
    J Gastrointest Cancer; 2024 Jun; 55(2):820-828. PubMed ID: 38308686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.
    Voncken FEM; Aleman BMP; van Dieren JM; Grootscholten C; Lalezari F; van Sandick JW; Steinberg JD; Vegt E
    Strahlenther Onkol; 2018 Feb; 194(2):156-163. PubMed ID: 29051991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.
    Kato H; Fukuchi M; Miyazaki T; Nakajima M; Tanaka N; Inose T; Kimura H; Faried A; Saito K; Sohda M; Fukai Y; Masuda N; Manda R; Ojima H; Tsukada K; Oriuchi N; Endo K; Nonaka T; Shioya M; Ishikawa H; Sakurai H; Nakano T; Kuwano H
    Anticancer Res; 2007; 27(4C):2627-33. PubMed ID: 17695425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [18F]fluoro-2-deoxyglucose-positron emission tomography for the assessment of histopathological response after preoperative chemoradiotherapy in advanced oral squamous cell carcinoma.
    Shimomura H; Sasahira T; Yamanaka Y; Kurihara M; Imai Y; Tamaki S; Yamakawa N; Shirone N; Hasegawa M; Kuniyasu H; Kirita T
    Int J Clin Oncol; 2015 Apr; 20(2):308-16. PubMed ID: 24942501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma.
    Huang YC; Li SH; Lu HI; Hsu CC; Wang YM; Lin WC; Chen CJ; Ho KW; Chiu NT
    PLoS One; 2019; 14(1):e0210055. PubMed ID: 30615636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
    Flamen P; Van Cutsem E; Lerut A; Cambier JP; Haustermans K; Bormans G; De Leyn P; Van Raemdonck D; De Wever W; Ectors N; Maes A; Mortelmans L
    Ann Oncol; 2002 Mar; 13(3):361-8. PubMed ID: 11996465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C; Torun N; Guler OC; Yildirim BA
    Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
    Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Chennupati SK; Quon A; Kamaya A; Pai RK; La T; Krakow TE; Graves E; Koong AC; Chang DT
    Am J Clin Oncol; 2012 Aug; 35(4):334-9. PubMed ID: 21422989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
    Erasmus JJ; Munden RF; Truong MT; Ho JJ; Hofstetter WL; Macapinlac HA; Correa AM; Wu TT; Bruzzi JF; Marom EM; Sabloff BS; Ajani JA; Komaki R; Liao Z; Lee JH; Fukami N; Bresalier R; Swisher SG
    J Thorac Oncol; 2006 Jun; 1(5):478-86. PubMed ID: 17409902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
    Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
    Jingu K; Kaneta T; Nemoto K; Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Takai Y; Takahashi S; Yamada S
    Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
    Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
    Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.